Nathan J Dowden
President & COO · 4 filings · Latest: Sep 2, 2026
Entrada Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
TRDA | Nathan J Dowden | President & COO | May 4, 2026 | Sale | $15.33 | 15,000 | $230.0K | 198,588 | |
TRDA | Nathan J Dowden | President & COO | May 4, 2026 | Option Exercise | $1.74 | 15,000 | $26.1K | 213,588 | |
TRDA | NATHAN DOWDEN | — | May 4, 2026 | Proposed Sale | $14.50 | 15,000 | $217.5K | — | |
TRDA | Nathan J Dowden | President & COO | Mar 10, 2026 | Sale | $13.05 | 11,894 | $155.2K | 198,588 | |
TRDA | Nathan J Dowden | President & COO | Mar 9, 2026 | Sale | $13.02 | 3,116 | $40.6K | 210,482 | |
TRDA | NATHAN DOWDEN | — | Mar 9, 2026 | Proposed Sale | $12.58 | 15,010 | $188.8K | — | |
TRDA | NATHAN DOWDEN | — | Sep 6, 2024 | Proposed Sale | $15.39 | 3,150 | $48.5K | — |